Tell us your experience of changing from Lamictal to Logem
Wednesday, 2 October 2019
From 01 Oct 2019, Pharmac only funds the generic brand of Lamotrigine, Logem. They no longer fund the Lamictal and Arrow brands.
To find out how the brand change affects people with epilepsy, Epilepsy New Zealand is creating a register of their experiences. Fill in this questionnaire to share your story with us.
If Logem affects you negatively, report your adverse event to Medsafe.
Who this is for
We’d like to hear from anyone with epilepsy who is changing, or has changed, from Lamictal to Logem. It doesn’t matter if you changed recently or some time ago.
If your child is changing brands, you’re welcome to fill it in on their behalf.
How we’ll use your information
We will save all survey data in a register, so we know how the brand change affects people with epilepsy. If you would like to give us your contact details, we’ll contact you again in three months to see how you’re getting on.
We will only publish the whole group’s responses, not individual responses. We won’t publish or forward your personal details to anyone.
Who to contact if you have questions
If you have questions, please contact either:
- your local educator at 0800 EPILEPSY (0800 37 45 37)
- our national office at firstname.lastname@example.org